- Investing Ideas
- /
- Global High Growth Potential Companies
Global High Growth Potential Companies
Results
8724
0 new
Companies with a Future performance score of at least 3, ordered by Future performance score.
8,724 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
RMDA | ج.م3.56 | -2.7% | 134.2% | ج.م5.4b | ج.م4.11 | PE23.6x | E30.2% | 1.9% | Pharmaceuticals & Biotech | ||
FWRY | ج.م8.46 | 2.3% | 65.2% | ج.م28.8b | ج.م11.39 | PE29.9x | E28.7% | n/a | Diversified Financials | ||
ICOP | €7.24 | 0.3% | n/a | €200.1m | €9.30 | PE39.6x | E49.2% | n/a | Capital Goods | ||
PHM | €74.55 | -7.7% | 98.8% | €1.3b | €84.60 | PE2102.1x | E56.4% | 0.9% | Pharmaceuticals & Biotech | ||
SRPT | US$104.54 | -14.0% | 25.7% | US$10.0b | US$189.86 | PE82x | E42.6% | n/a | Pharmaceuticals & Biotech | ||
ALKT | US$35.93 | -4.5% | 56.8% | US$3.6b | US$44.30 | PS11.4x | E98.6% | n/a | Software | ||
ZVRA | US$8.62 | -3.8% | 92.4% | US$460.1m | US$20.14 | PS18.8x | E73.7% | n/a | Pharmaceuticals & Biotech | ||
ONON | US$51.92 | -1.5% | 82.4% | US$16.6b | US$58.60 | PE117.2x | E29.7% | n/a | Consumer Durables | ||
NVDA | US$141.98 | -2.3% | 181.7% | US$3.5t | US$160.38 | PE65.7x | E23.3% | 0.03% | Semiconductors | ||
AXSM | US$93.17 | 2.4% | 55.2% | US$4.5b | US$129.41 | PS13.3x | E71.7% | n/a | Pharmaceuticals & Biotech | ||
EH | US$16.55 | -1.9% | 6.0% | US$1.0b | US$24.35 | PS30.4x | E81.4% | n/a | Capital Goods | ||
MBTN | CHF 0.44 | -58.9% | -99.8% | CHF 13.5m | CHF 6.03 | PS0.2x | E111.6% | n/a | Semiconductors | ||
GAU | CA$2.01 | 3.6% | 142.2% | CA$516.4m | CA$3.51 | PS2.2x | E89.2% | n/a | Materials | ||
CRDO | US$39.76 | -14.5% | 118.6% | US$6.6b | US$37.58 | PS30.3x | E95.0% | n/a | Semiconductors | ||
ACE | SEK 2.63 | -0.9% | -9.3% | SEK 252.2m | SEK 8.25 | PB2.3x | E47.2% | n/a | Pharmaceuticals & Biotech | ||
NVG | zł1.68 | -1.2% | -13.0% | zł58.8m | zł3.65 | PE217.1x | E41.3% | 3.6% | Diversified Financials | ||
ALNY | US$235.56 | -15.8% | 42.5% | US$30.4b | US$301.40 | PS14.5x | E70.7% | n/a | Pharmaceuticals & Biotech | ||
NEWBRY | SEK 3.82 | -4.0% | 4.9% | SEK 92.7m | SEK 8.00 | PS2.5x | E130.0% | n/a | Pharmaceuticals & Biotech | ||
ARES | US$167.21 | -2.4% | 54.3% | US$52.3b | US$172.31 | PE78.1x | E33.4% | 2.2% | Diversified Financials | ||
PRL | CA$35.67 | -6.6% | 265.8% | CA$1.2b | CA$43.32 | PE20.1x | E37.6% | 1.6% | Diversified Financials | ||
RHM | €575.80 | 1.9% | 106.5% | €25.0b | €639.40 | PE36.5x | E28.6% | 1.0% | Capital Goods | ||
TGTX | US$29.54 | -3.9% | 130.4% | US$4.2b | US$37.22 | PS16x | E56.5% | n/a | Pharmaceuticals & Biotech | ||
AGP | €7.34 | 6.4% | 46.2% | €127.1m | €12.85 | PE18.8x | E22.1% | n/a | Capital Goods | ||
MX1 | AU$0.069 | 1.5% | -46.9% | AU$40.1m | AU$0.19 | PS2.6x | E68.6% | n/a | Healthcare |